Clinical Trial

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Name: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis — clinical trial record (NCT07463521)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MyVision

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-17

Trial Details

NCT Number	NCT07463521
Lead Sponsor	UCB Biopharma SRL
Conditions	Ocular Myasthenia Gravis
Enrollment	120 participants
Start Date	2026-05-27
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-01-22 (estimated)
Updated on ClinicalTrials.gov	2026-06-16